Número 1 - EII al día

EII29. Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR Proteins:Role in Host-Microbial Interactions and Inflammatory Disease. AnnuRev Biochem 2004.30. Aldhous MC, Nimmo ER, Satsangi J. NOD2/CARD15 and the Panethcell: another piece in the genetic jigsaw of inflammatory bowel disease.Gut 2003;52:1533-5.31. Grimm MC, Pavli P. NOD2 mutations and Crohn's disease: are Panethcells and their antimicrobial peptides the link? Gut 2004;53:1558-60.32.*Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, et al. Crohn'sdisease and the NOD2 gene: a role for paneth cells. Gastroenterology2003;125:47-57.33.*Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FF, et al. Expressionof NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut2003;52:1591-7.Implicación de las células de Paneth en la expresión de NOD2.34. De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, LangelierD, et al. The role of the Toll receptor pathway in susceptibilityto inflammatory bowel diseases. Genes Immun 2007;8:387-97.35.*Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, etal. A genome-wide association study identifies IL23R as an inflammatorybowel disease gene. Science 2006;314:1461-3.Primera identificación del gen IL23R en la EICI.36. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, etal. Interleukin-23 drives innate and T cell-mediated intestinal inflammation.J Exp Med 2006;203:2473-83.37. Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS,et al. IL-23 plays a key role in Helicobacter hepaticus-induced T celldependentcolitis. J Exp Med 2006;203:2485-94.38. Tremelling M, Cummings F, Fisher SA, Mansfield J, Gwilliam R, KeniryA, et al. IL23R variation determines susceptibility but not disease phenotypein inflammatory bowel disease. Gastroenterology 2007;132:1657-64.39. Tremelling M, Parkes M. Genome-wide association scans identify multipleconfirmed susceptibility loci for Crohn's disease: lessons forstudy design. Inflamm Bowel Dis 2007;13:1554-60.40.*Massey DC, Parkes M. Genome-wide association scanning highlightstwo autophagy genes, ATG16L1 and IRGM, as being significantly associatedwith Crohn's disease. Autophagy 2007;3:649-51.Estudio de confirmación de genes involucrados en autofagia en la enfermedadde Crohn.41. Prescott NJ, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, et al.A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's diseaseand is independent of CARD15 and IBD5. Gastroenterology2007;132:1665-71.42.*Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, FisherSA, et al. Sequence variants in the autophagy gene IRGM andmultiple other replicating loci contribute to Crohn's disease susceptibility.Nat Genet 2007;39:830-2.Primera identificación del gen IRGM en la enfermedad de Crohn. Segundogene implicado en autofagia.43. Van Limbergen J, Russell RK, Nimmo ER, Drummond HE, Smith L,Anderson NH, et al. Autophagy gene ATG16L1 influences susceptibilityand disease location but not childhood-onset in Crohn's disease inNorthern Europe. Inflamm Bowel Dis 2008;14:338-46.44. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E,Schlee M, et al. NOD2 (CARD15) mutations in Crohn's disease areassociated with diminished mucosal alpha-defensin expression. Gut2004;53:1658-64.45.*Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, PetrasRE, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease.Proc Natl Acad Sci U S A 2005;102:18129-34.Se describe el papel de la defensinas como determinación de localizaciónen la enfermedad de Crohn.46.*Wehkamp J, Wang G, Kubler I, Nuding S, Gregorieff A, Schnabel A,et al. The Paneth Cell {alpha}-Defensin Deficiency of Ileal Crohn's DiseaseIs Linked to Wnt/Tcf-4. J Immunol 2007;179:3109-18.Se determina un gen primario específico de predisposición paraCrohn ileal en la vía Wnt y Tcf-4 importante para la diferenciación decélulas de Paneth47.*Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, BevinsCL, et al. A chromosome 8 gene-cluster polymorphism with lowhuman beta-defensin 2 gene copy number predisposes to Crohn diseaseof the colon. Am J Hum Genet 2006;79:439-48.Primer ejemplo de alteraciones en el número de copias de un gencomo predisposición de enfermedad .48. Pena AS. [The significance of CARD15 mutations in Crohn's disease.The Spanish contribution] El Significado de las mutaciones deCARD15 en la enfermedad de Crohn. La contribución Española. RevEsp Enferm Dig 2007;99:563-9.49. King K, Bagnall R, Fisher SA, Sheikh F, Cuthbert A, Tan S, et al. Identification,evolution, and association study of a novel promoter andfirst exon of the human NOD2 (CARD15) gene. Genomics 2007.50. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, et al.CARD15/NOD2 mutational analysis and genotype-phenotype correlationin 612 patients with inflammatory bowel disease. Am J HumGenet 2002;70:845-57.51.*Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differentialeffects of NOD2 variants on Crohn's disease risk and phenotypein diverse populations: a metaanalysis. Am J Gastroenterol2004;99:2393-404.Estudio que define la frecuencia geográfica de las mutaciones delNOD2.52. De Diego C, Alcantara M, Valle J, Perez-Grueso MJ, Munoz-Rosas C,Carrobles JM, et al. Frequency of CARD15 polymorphisms in patientswith Crohn's disease from Toledo, Spain: genotype-phenotype correlation.Genet Test 2006;10:178-85.53. Heresbach D, Gicquel-Douabin V, Birebent B, D'Halluin P N, Heresbach-LeBerre N, Dreano S, et al. NOD2/CARD15 gene polymorphismsin Crohn's disease: a genotype- phenotype analysis. Eur JGastroenterol Hepatol 2004;16:55-62.54. Crawford NP, Colliver DW, Eichenberger MR, Funke AA, Kolodko V,Cobbs GA, et al. CARD15 genotype-phenotype relationships in a smallinflammatory bowel disease population with severe disease affectionstatus. Dig Dis Sci 2007;52:2716-24.55.*Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, OrchardTR, et al. The molecular classification of the clinical manifestationsof Crohn's disease. Gastroenterology 2002;122:854-66.Estudio pionero de clasificación molecular de la enfermedad de Crohnbasado en marcadores genéticos.56. Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency,intestinal microbes, and the clinical phenotypes of Crohn's disease.J Leukoc Biol 2005;77:460-5.57. Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV, Burek CL, DattaL, et al. Antibodies to saccharomyces cerevisiae in Crohn's disease:higher titers are associated with a greater frequency of mutantNOD2/CARD15 alleles and with a higher probability of complicateddisease. Inflamm Bowel Dis 2007;13:143-51.58. Brant SR, Wang MH, Rawsthorne P, Sargent M, Datta LW, Nouvet F,et al. A population-based case-control study of CARD15 and other riskfactors in Crohn's disease and ulcerative colitis. Am J Gastroenterol2007;102:313-23.59. de Diego C, Alcantara M, Valle J, Repiso A, Carrobles JM, Martinez-Castro P. Influence of smoking habits and CARD15 mutations on theonset of Crohn's disease. Scand J Gastroenterol 2006;41:1209-11.60. Laine ML, Farre MA, Garcia-Gonzalez MA, van Dijk LJ, Ham AJ, WinkelEG, et al. [Risk factors in adult periodontitis: polymorphism inthe interleukin-1 gene family]. Ned Tijdschr Tandheelkd 2002;109:303-6.61. Laine ML, Murillo LS, Morre SA, Winkel EG, Pena AS, van WinkelhoffAJ. CARD15 gene mutations in periodontitis. J Clin Periodontol2004;31:890-3.62. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: areview of epidemiology, pathophysiology, and therapeutic implications.Inflamm Bowel Dis 2004;10:848-59.12 ENFERMEDAD INFLAMATORIA INTESTINAL AL DÍA